Displaying 190 (all) recruiting clinical trials.
-
HYPO2-BOOST GBM trial: Hypoxia-targeted radiotherapy boost for GBM
This is a Phase 1/2 study that will be testing whether a special MRI scan, called dynamic contrast-enhanced MRI (DSC-MRI), can help doctors find ...
Phase
Interventional
-
A Phase 2 Randomized Blinded Placebo Controlled Trial Investigating the Efficacy and Safety of Visugromab plus Nivolumab with or without Docetaxel versus Docetaxel Monotherapy in Second Line Treatment of Participants with Metastatic Non Squamous Non Small Cell Lung Cancer (GDFATHER NSCLC 02)
This is a Phase 2 study testing the drug visugromab (a GDF-15 neutralizing antibody) in people with non-squamous non-small cell lung cancer (NSCLC) who are ...
Phase
Interventional
-
A Phase 1a/1b Open-Label Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of BBO-11818 in Subjects with Advanced KRAS Mutant Cancers
This is a Phase 1 study testing whether the study medicine BBO-11818 (a pan-KRAS inhibitor) is safe and effective in patients with locally advanced solid ...
Phase
Interventional
-
CAN-2409-LuTK03: A Phase 3 Multicenter Randomized Open Label Clinical Trial of aglatimagene besadenovec (CAN 2409) Plus Prodrug and Pembrolizumab Versus Docetaxel in Patients with Stage IV Non Squamous Non Small Cell Lung Cancer Progressing on Pembrolizumab-based Treatment
This is a global, Phase 3 study testing a new treatment for adults with stage IV non-squamous non-small cell lung cancer (NSCLC) whose cancer has ...
Phase
Interventional
-
A Phase 2 Open-label Study of VS-7375 an Oral KRAS G12D (ON/OFF) Inhibitor in Patients with Previously Treated Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)
This is a Phase II study for people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called a KRAS G12D ...
Phase
Interventional
-
A Randomized Double-Blind Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated KRAS G12D Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
This is a Phase 3 study for people with metastatic pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. To join the study ...
Phase
Interventional
-
A Modular Phase I/II Open-label Multicentre Study to Evaluate the Safety Tolerability and Efficacy of AZD3470 a PRMT5 Inhibitor as Monotherapy and in Combination With Anticancer Agent(s) in Participants With Relapsed/Refractory Haematologic Malignancies
This is a Phase I/II, open-label, multicentre clinical study that is testing AZD3470, an investigational oral medicine, in people with blood cancers (haematologic malignancies ...
Phase
Interventional
-
A Phase 1b Open-label Study of CLN-978 for the Treatment of Active Moderate to Severe Sjogren s Disease
The purpose of this study is to investigate the safety, tolerability, and effectivness of an investigational drug called CLN-978 in patients with active Sjogren’s ...Phase
Interventional
-
A Phase III Multicentre Randomised Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1)
This is a Phase III study testing a new treatment for people with untreated follicular lymphoma (FL). The study will compare surovatamig combined with rituximab ...
Phase
Interventional
-
A Phase II Study of the Interferon Gamma Inhibitor Emapalumab for Prophylaxis of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients with Lymphoma and Multiple Myeloma Receiving Bispecific T-Cell Engagers.
This is a Phase 2, non-randomized study testing emapalumab, a medicine that blocks a protein called interferon gamma (IFN-y). The goal of this study is ...
Phase
Interventional
